Ambit Biosciences
Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases.[1]: 3 [n 1] As of March 2014[update], the company was based in San Diego, California and consisted of a single facility.[2]: 58 Ambit made an initial public offering in May 2013[2] and was listed on the NASDAQ exchange under the symbol "AMBI".[3] Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.
Products
As of March 2014[update], three products were under development, of which quizartinib was their lead drug candidate.[1]: 3
Business model
As of March 2014[update], Ambit sought to develop new therapeutics through internal, proprietary research, which is evidenced by their pipeline of three products consisting entirely of internally developed therapeutics.[1]: 3 Further, Ambit aimed to be a full life cycle pharmaceutical company by conducting discovery, development and further commercialization of therapeutics.[1]: 3
Among the firms who invested heavily in Ambit prior to its initial public offering was Foresite Capital in January 2013.[3]
In November of 2014, Ambit was acquired by Daiichi Sankyo.[4]
References
- ^ a b c d "Form 10-K: Ambit Biosciences Corporation. Commission file number: 001-35919". EDGAR. U.S. Securities and Exchange Commission. March 20, 2014. Retrieved 2017-06-27.
{{cite web}}
: Cite has empty unknown parameter:|dead-url=
(help) - ^ a b Huggett, Brady (December 2013). "Burning bright". Nature Biotechnology. 31 (12): 1068–1071. doi:10.1038/nbt.2766.
- ^ a b Fidler, Ben (2014-04-01). "Foresite Capital Reloads With New $300M Late-Stage Biotech Fund". Xconomy. Retrieved 2017-06-27.
{{cite news}}
: Cite has empty unknown parameter:|dead-url=
(help) - ^ Fikes, Bradley J. (2017-01-16). "Local biotech turning to Japan for partnerships". The San Diego Union-Tribune. Retrieved 2017-06-27.
{{cite news}}
: Cite has empty unknown parameter:|dead-url=
(help)
Notes
- ^ The SEC 10K submission for 2013 indicates that the company is a "biopharmaceutical" company, which implies that they are primarily developing biopharmaceuticals; however their lead product is a small molecule therapeutic, calling into question the term used in the SEC submission.